Fibroblast activation protein-specific mri provides Improved tumour mapping in an orthotopic model of Prostate cancer compared to prostate specific Membrane antigen
Date
2022
Authors
Dmochowska, N.
Milanova, V.
Shetty, A.
Mukkamala, R.
Srinivasarao, M.
Walser, E.
Low, P.
Thierry, B.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Conference item
Citation
Journal of Urology, 2022, vol.207, iss.Suppl. 5, pp.E101-E102
Statement of Responsibility
Nicole Dmochowska, Valentina Milanova, Anil Shetty, Ramesh Mukkamala, Madduri Srinivasarao, Eric Walser, Phil Low, and Benjamin Thierry
Conference Name
AUA Annual Meeting (13 May 2022 - 16 May 2022 : New Orleans, United States)
Abstract
MRI guided focal therapies of prostate cancer have the potential to reduce treatment related side effects without sacrificing oncological outcomes. Molecular MRI with agents targeted to tumour tissues enhances tumour margin detection and consequently treatment guidance/planning. Prostate specific membrane antigen (PSMA) expression is currently the gold standard for molecular imaging of prostate cancer. Fibroblast activation protein (FAP) is an extracellular transmembrane protein expressed on cells of the tumour microenvironment, particularly in stromal and vascular components. FAP has been gaining momentum as a pan-cancer marker(DOI: 10.2967/jnumed.119.227967) as its overexpression often correlates with cancer severity, including in prostate cancer (DOI: 10.1371/journal.pone.0116683) and has been found to be negligibly expressed in healthy tissue. Our objective was to compare MRI contrast of PSMA-targeting and FAP-targeting magnetic nanoparticles (MNPs) in an orthotopic murine model of prostate cancer.
School/Discipline
Dissertation Note
Provenance
Description
Abstract number PD07-08
Access Status
Rights
© 2022 by American Urological Association Education and Research, Inc.